Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2013

Open Access 01-12-2013 | Research

Hodgkin’s lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms

Authors: Laura Cella, Manuel Conson, Maria Cristina Pressello, Silvia Molinelli, Uwe Schneider, Vittorio Donato, Roberto Orecchia, Marco Salvatore, Roberto Pacelli

Published in: Radiation Oncology | Issue 1/2013

Login to get access

Abstract

Background

Purpose of this study is to explore the trade-offs between radio-induced toxicities and second malignant neoplasm (SMN) induction risk of different emerging radiotherapy techniques for Hodgkin’s lymphoma (HL) through a comprehensive dosimetric analysis on a representative clinical model.

Methods

Three different planning target volume (PTVi) scenarios of a female patient with supradiaphragmatic HL were used as models for the purpose of this study. Five treatment radiation techniques were simulated: an anterior-posterior parallel-opposed (AP-PA), a forward intensity modulated (FIMRT), an inverse intensity modulated (IMRT), a Tomotherapy (TOMO), a proton (PRO) technique. A radiation dose of 30 Gy or CGE was prescribed. Dose-volume histograms of PTVs and organs-at-risk (OARs) were calculated and related to available dose-volume constraints. SMN risk for breasts, thyroid, and lungs was estimated through the Organ Equivalent Dose model considering cell repopulation and inhomogeneous organ doses.

Results

With similar level of PTVi coverage, IMRT, TOMO and PRO plans generally reduced the OARs’ dose and accordingly the related radio-induced toxicities. However, only TOMO and PRO plans were compliant with all constraints in all scenarios. For the IMRT and TOMO plans an increased risk of development of breast, and lung SMN compared with AP-PA and FIMRT techniques was estimated. Only PRO plans seemed to reduce the risk of predicted SMN compared with AP-PA technique.

Conclusions

Our model–based study supports the use of advanced RT techniques to successfully spare OARs and to reduce the risk of radio-induced toxicities in HL patients. However, the estimated increase of SMNs’ risk inherent to TOMO and IMRT techniques should be carefully considered in the evaluation of a risk-adapted therapeutic strategy.
Appendix
Available only for authorised users
Literature
1.
Hodgson DC: Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011, 2011: 323-329. 10.1182/asheducation-2011.1.323CrossRefPubMed
2.
Ng AK: Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011,154(1):23-31. 10.1111/j.1365-2141.2011.08713.xCrossRefPubMed
3.
Elkin EB, Klem ML, Gonzales AM: Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol 2011,29(18):2466-2473. 10.1200/JCO.2010.32.4079CrossRefPubMedPubMedCentral
4.
Hoppe BS, Flampouri S, Lynch J: Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy. Oncology (Williston Park) 2012,26(5):456-459. 462–455
5.
Hoppe BS, Flampouri S, Su Z: Effective Dose Reduction to Cardiac Structures Using Protons Compared with 3DCRT and IMRT in Mediastinal Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 2012,84(2):449-455. 10.1016/j.ijrobp.2011.12.034CrossRefPubMed
6.
Li J, Dabaja B, Reed V: Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys 2011,81(1):167-174. 10.1016/j.ijrobp.2010.05.007CrossRefPubMed
7.
Lu NN, Li YX, Wu RY: Dosimetric and Clinical Outcomes of Involved-Field Intensity-Modulated Radiotherapy After Chemotherapy for Early-Stage Hodgkin's Lymphoma With Mediastinal Involvement. Int J Radiat Oncol Biol Phys 2012,84(1):210-216. 10.1016/j.ijrobp.2011.11.008CrossRefPubMed
8.
Vlachaki MT, Kumar S: Helical tomotherapy in the radiotherapy treatment of Hodgkin's disease - a feasibility study. J Appl Clin Med Phys 2010,11(1):3042.PubMed
9.
Nieder C, Schill S, Kneschaurek P: Comparison of three different mediastinal radiotherapy techniques in female patients: Impact on heart sparing and dose to the breasts. Radiother Oncol 2007,82(3):301-307. 10.1016/j.radonc.2006.10.015CrossRefPubMed
10.
Fiandra C, Filippi AR, Catuzzo P: Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin's lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 2012,7(1):186. 10.1186/1748-717X-7-186CrossRefPubMedPubMedCentral
11.
De Sanctis V, Bolzan C, D'Arienzo M: Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy? Radiat Oncol 2012, 7: 129. 10.1186/1748-717X-7-129CrossRefPubMedPubMedCentral
12.
Fox AM, Dosoretz AP, Mauch PM: Predictive factors for radiation pneumonitis in hodgkin lymphoma patients receiving combined-modality therapy. Int J Radiat Oncol Biol Phys 2012,83(1):277-283. 10.1016/j.ijrobp.2011.05.078CrossRefPubMed
13.
Cella L, Conson M, Caterino M: Thyroid V30 Predicts Radiation-Induced Hypothyroidism in Patients Treated With Sequential Chemo-Radiotherapy for Hodgkin's Lymphoma. Int J Radiat Oncol Biol Phys 2012,82(5):1802-1808. 10.1016/j.ijrobp.2010.09.054CrossRefPubMed
14.
Cella L, Liuzzi R, Conson M: Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin's lymphoma. Radiother Oncol 2011,101(2):316-321. 10.1016/j.radonc.2011.08.040CrossRefPubMed
15.
Gagliardi G, Constine LS, Moiseenko V: Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010,76(3 Suppl):S77-85.CrossRefPubMed
16.
Hall EJ, Wuu CS: Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003,56(1):83-88. 10.1016/S0360-3016(03)00073-7CrossRefPubMed
17.
18.
Berrington De Gonzalez A, Gilbert E, Curtis R: Second Solid Cancers After Radiation Therapy: A Systematic Review of the Epidemiologic Studies of the Radiation Dose–response Relationship. Int J Radiat Oncol Biol Phys 2012. Epub ahead of print
19.
Schneider U: Mechanistic model of radiation-induced cancer after fractionated radiotherapy using the linear-quadratic formula. Med Phys 2009,36(4):1138-1143. 10.1118/1.3089792CrossRefPubMed
20.
Schneider U, Sumila M, Robotka J: Site-specific dose–response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol Med Model 2011, 8: 27. 10.1186/1742-4682-8-27CrossRefPubMedPubMedCentral
21.
Schneider U, Sumila M, Robotka J: Dose–response relationship for breast cancer induction at radiotherapy dose. Radiat Oncol 2011, 6: 67. 10.1186/1748-717X-6-67CrossRefPubMedPubMedCentral
22.
Shuryak I, Hahnfeldt P, Hlatky L: A new view of radiation-induced cancer: integrating short- and long-term processes. Part I: approach. Radiat Environ Biophys 2009,48(3):263-274. 10.1007/s00411-009-0230-3CrossRefPubMedPubMedCentral
23.
Shuryak I, Hahnfeldt P, Hlatky L: A new view of radiation-induced cancer: integrating short- and long-term processes. Part II: second cancer risk estimation. Radiation and environmental biophysics 2009,48(3):275-286. 10.1007/s00411-009-0231-2CrossRefPubMedPubMedCentral
24.
Cella L, Liuzzi R, Magliulo M: Radiotherapy of large target volumes in Hodgkin's lymphoma: normal tissue sparing capability of forward IMRT versus conventional techniques. Radiat Oncol 2010,5(1):33. 10.1186/1748-717X-5-33CrossRefPubMedPubMedCentral
25.
Feng M, Moran JM, Koelling T: Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011,79(1):10-18. 10.1016/j.ijrobp.2009.10.058CrossRefPubMedPubMedCentral
26.
Weber DC, Peguret N, Dipasquale G: Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 2009,75(5):1578-1586. 10.1016/j.ijrobp.2009.05.012CrossRefPubMed
27.
D'Errico F, Luszik-Bhadra M, Nath R: Depth dose-equivalent and effective energies of photoneutrons generated by 6–18 MV X-ray beams for radiotherapy. Health Phys 2001,80(1):4-11. 10.1097/00004032-200101000-00003CrossRefPubMed
28.
Schneider U, Agosteo S, Pedroni E: Secondary neutron dose during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys 2002,53(1):244-251. 10.1016/S0360-3016(01)02826-7CrossRefPubMed
29.
Engert A, Plutschow A, Eich HT: Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma. N Engl J Med 2010,363(7):640-652. 10.1056/NEJMoa1000067CrossRefPubMed
30.
Campbell BA, Hornby C, Cunninghame J: Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol 2012,23(5):1259-1266. 10.1093/annonc/mdr439CrossRefPubMed
31.
ICRP: Relative Biological Effectiveness, Radiation Weighting and Quality Factor". ICRP Publication 92. Ann. ICRP 33 (4). 2003.
32.
Edwards AA, Lloyd DC, Prosser JS: Chromosome aberrations induced in human lymphocytes by 8.7 MeV protons and 23.5 MeV helium-3 ions. Int J Radiat Biol Relat Stud Phys Chem Med 1986,50(1):137-145. 10.1080/09553008614550511CrossRefPubMed
33.
NCRP: The relative biological effectiveness of radiations of different quality. NCRP Report 104. 1990.
34.
35.
Schippers JM, Lomax AJ: Emerging technologies in proton therapy. Acta Oncol 2011,50(6):838-850. 10.3109/0284186X.2011.582513CrossRefPubMed
Metadata
Title
Hodgkin’s lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms
Authors
Laura Cella
Manuel Conson
Maria Cristina Pressello
Silvia Molinelli
Uwe Schneider
Vittorio Donato
Roberto Orecchia
Marco Salvatore
Roberto Pacelli
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2013
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-8-22

Other articles of this Issue 1/2013

Radiation Oncology 1/2013 Go to the issue

Research

CBCT-based volumetric and dosimetric variation evaluation of volumetric modulated arc radiotherapy in the treatment of nasopharyngeal cancer patients

Research

Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer

Methodology

Atlas-based automatic segmentation of head and neck organs at risk and nodal target volumes: a clinical validation

Research

Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma

Research

Assessment of organ dose reduction and secondary cancer risk associated with the use of proton beam therapy and intensity modulated radiation therapy in treatment of neuroblastomas

Research

Tumor volume is an independent prognostic indicator of local control in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy